Madrid, LolaBassat Orellana, Quique2020-02-172020-02-172020-022214-109Xhttps://hdl.handle.net/2445/150433A decade ago, the astonishing and unexpected results of a trachoma trial in Ethiopia1 hinted at the exciting potential of mass azithromycin distribution to significantly reduce all-cause mortality in children by approximately 50%. In 2018, the Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) multi-country study,2, 3 designed to investigate the effect of mass biannual azithromycin distribution on all-cause mortality in children aged 1–59 months in sub-Saharan African communities, corroborated these results—although with more modest and credible findings than the trachoma trial.1 The greatest reduction in all-cause mortality was observed in Niger, the site with the highest baseline mortality, where biannual mass distribution of azithromycin to children aged 1–59 months decreased all-cause mortality by 18% compared with placebo.2 p.application/pdfengcc by-nc-nd (c) Madrid et al., 2020http://creativecommons.org/licenses/by-nc-nd/3.0/es/TracomaMortalitat infantilTrachomaInfant mortalityinfo:eu-repo/semantics/article2020-02-14info:eu-repo/semantics/openAccess31981547